key: cord-0715704-z7howr7q
authors: Doughty, Hayden; Barton, Dorothea
title: Severe Non-anaphylactic Allergic Reaction to the Pfizer-BioNTech COVID-19 vaccine
date: 2021-11-26
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.11.015
sha: 2242ccf9d58bbbecef4e183046dbc4f54d1ad900
doc_id: 715704
cord_uid: z7howr7q

nan

The Pfizer-BioNTech COVID-19 vaccine was first approved for use in December 2020. Studies 25 have shown the vaccine to be highly effective at preventing COVID-19 transmission and severity 26 of illness. 1 Reported side effects of the vaccine include injection site pain, mild-to-moderate 27 fatigue, mild-to-moderate headache, and more rarely, anaphylaxis and non-anaphylactic allergic 28 reactions. 2 Here, we describe a severe non-anaphylactic allergic reaction to the Pfizer-BioNTech 29 COVID-19 vaccine in a patient without a significant history of atopy. 30

A 36-year-old female developed a pruritic, painful rash on her arms, forearms, face, scalp, and 32 back of neck three hours after receiving the first dose of the Pfizer-BioNTech COVID-19 33 vaccine injected into the right deltoid. The rash persisted and the patient's eyelids began swelling 34 four days later. The patient took several doses of loratadine 10mg but did not notice significant 

COVID-arm": a 104 clinical and histological characterization

Asymmetric cutaneous vasculitis 107 following COVID-19 vaccination with unusual eosinophil preponderance

Pityriasis rosea-like 110 eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine

Ribonucleic acid COVID-19 vaccine-associated 113

cutaneous adverse drug events: a case series of two patients

The art of prevention

vaccine preparedness for the dermatologist

Allergy to COVID-19 vaccines: A current update